How long do drug patents last? US and UK protection rules
Drug patents usually last 20 years from filing, not approval. See how US exclusivity, UK SPCs and Orange Book dates affect generic entry planning.
Drug patents generally last 20 years from the relevant filing date, not from the medicine's approval. In the US and UK, additional protection and separate regulatory exclusivity can restrict generic entry beyond a patent's expiry (FDA, UK IPO).
For regulatory and portfolio teams, that means a patent expiration date alone cannot establish a generic-launch date. Patent rights and regulatory exclusivity run under different rules, and their periods can overlap. Don't add them together as consecutive blocks of protection (FDA).
US drug patent duration and extensions
The standard 20-year term does not mean 20 years of sales after FDA approval. The relevant filing date starts the clock. Other factors can affect a patent's duration (FDA patent FAQ).
A qualifying patent can receive an extension for regulatory review of up to five years. The remaining patent term at approval plus that extension is subject to a 14-year post-approval limit. This limit controls the extension calculation, not every unextended patent's remaining life (USPTO extension rules).
Extension is not automatic. The patent must be unexpired and meet statutory eligibility conditions, ordinarily including the product's first permitted commercial marketing. Only one patent can receive an extension for the same regulatory review period (USPTO eligibility rules).
FDA exclusivity is separate from a patent
FDA exclusivity can affect generic applications or approval even when no patent remains. Its scope depends on the protection awarded, rather than a single rule for the whole medicine (FDA).
| Protection | Period | What the period means |
|---|---|---|
| New chemical entity | Five years | Generally blocks covered generic and 505(b)(2) submissions. A qualifying Paragraph IV application can be submitted after four years, not launched then. |
| New clinical investigations | Three years | Covers relevant approved conditions or changes supported by essential clinical investigations conducted or sponsored by the applicant. Excludes bioavailability studies. |
| Orphan drug | Seven years | Applies within the eligible orphan-exclusivity scope, not to every competing medicine for the disease. |
| Pediatric | Six months | Adds to qualifying existing patent or exclusivity protection. It is not a standalone patent or an automatic reward for any pediatric study. |
The FDA regulations set out the five- and three-year protections. FDA's patent and exclusivity FAQ explains orphan and pediatric periods.
Three-year exclusivity does not necessarily cover every use or version of a drug. For an application that changes an approved product, check which conditions the protected investigations support before treating that period as a barrier (FDA regulations).
How long do drug patents last in the UK?
UK patents last up to 20 years from filing, with annual renewals needed to keep them in force (UK IPO, Patents Act). A supplementary protection certificate, or SPC, starts when the basic patent expires and can last up to five years. An eligible medicinal SPC can receive a further six-month paediatric extension. The SPC gives similar protection without extending the underlying patent's term (IPO SPC guidance).
Separate regulatory protection generally provides eight years of data protection and prevents generic sale or supply before ten years. A qualifying new indication with significant clinical benefit can increase the ten-year period to eleven years. The indication must be authorised within the first eight years. The extra year is awarded only once (MHRA application guidance).
Check the relevant initial authorisation when calculating these periods. Do not assume that conversion of an EU authorisation restarts the protection clock (MHRA reference-product guidance).
How to check a drug's patent expiration dates
For a US Orange Book check, use the following sequence:
- Match the application number and product number. Each strength is a separate product.
- Review the listed patent expiration dates, which the application holder submits, including applicable extensions.
- Check drug-substance and drug-product flags, plus use codes for patents covering approved indications or uses.
- Read the separate exclusivity codes and expiration dates.
These fields are described in the FDA Orange Book data documentation. One strength's record should not stand in for the whole brand.
RegAffairs AI explains these US and UK rules in its answer on drug patent duration.
Before using an expiry in a launch plan, assess the relevant patents and applicable approval barriers. Patent certifications and infringement proceedings can affect FDA approval timing, so the earliest listed expiry is not a guaranteed launch date (FDA patent-certification guidance).